New real-world data from the REPATHA-CE study suggest that evolocumab (Repatha®) is associated with significantly lower long-term risk of major adverse cardiovascular events (MACE) among adults with established atherosclerotic cardiovascular…
Evolocumab Associated with Lower Long-term Cardiovascular Event Risk in Real-world Study of More Than 110 000 Patients
